Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 72, n. 1, p. 167, doi. 10.1007/s00280-013-2182-1
- By:
- Publication type:
- Article
Works by Thai, Hoai‐Thu
Results: 11
1
2
A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models A comparison of bootstrap approaches for estimating uncertainty of parameters in linear mixed-effects models.
- Published in:
- Pharmaceutical Statistics, 2013, v. 12, n. 3, p. 129, doi. 10.1002/pst.1561
- By:
- Publication type:
- Article
3
Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics.
- Published in:
- Journal of Pharmacokinetics & Pharmacodynamics, 2014, v. 41, n. 1, p. 15, doi. 10.1007/s10928-013-9343-z
- By:
- Publication type:
- Article
4
Joint modelling and simulation of M‐protein dynamics and progression‐free survival for alternative isatuximab dosing with pomalidomide/dexamethasone.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 5, p. 2052, doi. 10.1111/bcp.15123
- By:
- Publication type:
- Article
5
Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
- Published in:
- British Journal of Clinical Pharmacology, 2015, v. 80, n. 3, p. 534, doi. 10.1111/bcp.12702
- By:
- Publication type:
- Article
6
Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics.
- Published in:
- Biometrics, 2022, v. 78, n. 1, p. 300, doi. 10.1111/biom.13433
- By:
- Publication type:
- Article
7
Isatuximab–dexamethasone–pomalidomide combination effects on serum M protein and PFS in myeloma: Development of a joint model using phase I/II data.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 12, p. 2087, doi. 10.1002/psp4.13206
- By:
- Publication type:
- Article
8
Joint modeling of tumor dynamics and progression‐free survival in advanced breast cancer: Leveraging data from amcenestrant early phase I–II trials.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 6, p. 941, doi. 10.1002/psp4.13128
- By:
- Publication type:
- Article
9
Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 12, p. 1846, doi. 10.1002/psp4.12947
- By:
- Publication type:
- Article
10
Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 6, p. 766, doi. 10.1002/psp4.12789
- By:
- Publication type:
- Article
11
PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 8, p. 928, doi. 10.1002/psp4.12666
- By:
- Publication type:
- Article